Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.

Caring for someone with multiple myeloma can be challenging on many levels. The person who has just been diagnosed may look to you for information to help them better understand the disease to ...

Biologic heterogeneity in myeloma supports subtype-specific approaches, and t(4;14) defines a clinically meaningful subset with distinct pathway activation and historically aggressive behavior.

bDepartment of Biostatistics and Epidemiology, University Hospital of Saint-Louis, Paris, France cDepartment of Hematology, University Hospital of Saint-Louis, Paris, France dDepartment of Hematology, ...

In a retrospective study, the non-relapse mortality rate at 1 year was 17% in those with CAR T-cell therapy-associated immune-related adverse events versus 2.7% in those without such events.

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...

Daratumumab and hyaluronidase-fihj is now FDA-approved for newly diagnosed multiple myeloma patients ineligible for ASCT, in combination with VRd. The phase 3 CEPHEUS trial showed significant ...

Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II) For over half a ...

D-VRd is the first anti-CD38 antibody-based regimen approved for all newly diagnosed multiple myeloma patients, regardless of transplant eligibility. The CEPHEUS trial demonstrated significant ...